CenTrial Logo

Upadacitinib: A New Hope for Crohn's Disease Patients

by


Clinical trial finds upadacitinib effective for Crohn's disease remission

Crohn's disease is a chronic inflammatory bowel disease that affects the digestive tract. It can occur at any age but often begins in teens and young adults. Symptoms include abdominal pain, diarrhea, fatigue, and weight loss. The exact cause is unclear, but genetics and the immune system play a role.

Crohn's is not curable, but treatments aim to manage symptoms and reduce inflammation. Medications, lifestyle changes, and sometimes surgery are used. Flare-ups, where symptoms worsen, can occur periodically. Working with healthcare providers to create a personalized treatment plan for better management of Crohn's disease and improved quality of life is essential.

Clinical Trial

Scientists studied a potential treatment for Crohn's disease using upadacitinib, which targets the Janus kinase (JAK) pathway. They conducted two phase 3 trials to assess the drug's effectiveness in inducing and maintaining remission. In the first trials (U-EXCEL and U-EXCEED), patients with moderate-to-severe Crohn's disease were randomly assigned to receive either upadacitinib or a placebo daily for 12 weeks. In the U-ENDURE maintenance trial, patients who responded well to upadacitinib during induction were assigned to receive different doses of the drug or placebo daily for 52 weeks.

Results

In the U-EXCEL and U-EXCEED trials, more patients who received upadacitinib achieved clinical remission and endoscopic response compared to the placebo group. In the U-ENDURE trial, the upadacitinib group showed better outcomes, with higher percentages of patients achieving clinical remission and endoscopic response.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Adverse Effects

More cases of herpes zoster infections were observed in the upadacitinib groups, and there were also reports of hepatic disorders, neutropenia, and gastrointestinal perforations.

Conclusion

Upadacitinib demonstrated superior efficacy in inducing and maintaining remission in patients with moderate-to-severe Crohn's disease compared to a placebo. This research provides valuable insights into potential new treatment options for this challenging condition. However, researchers must carefully consider and address the observed side effects before implementing the drug widely.
__________



Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.